Julia Esther Colunga Pedraza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Esther Colunga Pedraza has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Perla Rocío Colunga Pedraza
Servicio de Hematología, Hospital Universitario Dr José Eleuterio González, UANL, Monterrey, Mexico
9 shared publications - Oscar González-Llano
Universidad Autonóma de Nuevo León
6 shared publications - Yajaira Valentine Jimenez-Antolinez
Universidad Autonóma de Nuevo León
6 shared publications - Samantha Paulina Peña-Lozano
Department of Hematology. Monterrey, Universidad Autónoma de Nuevo León, Hospital Universitario ¨Dr. José Eleuterio González¨, México
4 shared publications - Andrés Gómez-De León
Hematology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autonoma de Nuevo León, Monterrey, Mexico
3 shared publications - David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 128-131
Case series of desensitization to pegylated escherichia coli–derived asparaginase
Introduction: Asparaginase is an integral component in the treatment of acute lymphoblastic leukemia. The asparaginase products available in our country are Escherichia Coli (E. Coli)-derived asparaginase (Leunase), pegaspargase (Oncaspar), and, to a lesser extent, Erwinia chrysanthemi-derived asparaginase. Hypersensitivity reactions (HSR) are reported less frequently in those receiving pegaspargase, ranging from 3% to 15%; however, these reactions can limit its use in this population.Case report: We present four patients with B-cell ALL who experienced a severe allergic HSR, anaphylaxis, leading us to perform a 12-step desensitization protocol to pegaspargase to ensure that the patients received first-line treatment for their oncologic condition. Management and outcomes: Skin tests were performed, with positive results in two out of four patients. Subsequently, a 12-step desensitization protocol was carried out. Pegaspargase was diluted with 0.9% saline solution in three bags (concentrations 1:100, 1:10, and 1:1). Infusions used four steps per bag titrated every 15 minutes up to a maximum rate of 80 mL/ hour for step 12. A successful administration of pegaspargase was achieved, and the patients continued with their ALL treatment.
- 1 July 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (4) , 128-131
Open AccessCase series of desensitization to pegylated escherichia coli–derived asparaginase
Introduction: Asparaginase is an integral component in the treatment of acute lymphoblastic leukemia. The asparaginase products available in our country are Escherichia Coli (E. Coli)-derived asparaginase (Leunase), pegaspargase (Oncaspar), and, to a lesser extent, Erwinia chrysanthemi-derived asparaginase. Hypersensitivity reactions (HSR) are reported less frequently in those receiving pegaspargase, ranging from 3% to 15%; however, these reactions can limit its use in this population.Case report: We present four patients with B-cell ALL who experienced a severe allergic HSR, anaphylaxis, leading us to perform a 12-step desensitization protocol to pegaspargase to ensure that the patients received first-line treatment for their oncologic condition. Management and outcomes: Skin tests were performed, with positive results in two out of four patients. Subsequently, a 12-step desensitization protocol was carried out. Pegaspargase was diluted with 0.9% saline solution in three bags (concentrations 1:100, 1:10, and 1:1). Infusions used four steps per bag titrated every 15 minutes up to a maximum rate of 80 mL/ hour for step 12. A successful administration of pegaspargase was achieved, and the patients continued with their ALL treatment.
- 12 May 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey
Introduction: High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequently limited in low- and middle-income countries (LMICs). In Mexico, variability in HD-MTX practices may compromise treatment safety and efficacy. This study aimed to characterize national practice patterns and identify context-specific adaptations in the delivery of HD-MTX in resource constrained settings. Methods: A nationwide, cross-sectional electronic survey was conducted between May and November 2023 among pediatric hematologists and oncologists treating patients younger than 18 years with ALL. The questionnaire assessed institutional guidelines, availability of pharmacokinetic monitoring, and supportive care practices, including hydration, urinary alkalinization, and folinic acid rescue. Data were analyzed descriptively. Results: A total of 111 specialists from 27 Mexican states participated. Only 56% reported having institutional HD-MTX guidelines. While 97% administered HD-MTX to high-risk ALL patients, only 61% used full protocol-recommended doses, and nearly one-third reported dose reductions. Methotrexate plasma level monitoring was only available in 56% of centers. Most centers (86%) administered HD-MTX exclusively in the inpatient setting. Supportive care practices varied substantially across institutions and risk groups. Reported barriers included limited laboratory capacity (61%), lack of standardized protocols (44%), and delays related to bed availability (39%). Conclusions: Optimizing HD-MTX delivery in Mexico requires integrating standardized clinical practices with targeted system-level interventions to ensure timely access to pharmacokinetic monitoring. The development and implementation of context-adapted national guidelines may improve safety, reduce variability in care, and mitigate outcome disparities in children with ALL.
- 12 May 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey
Introduction: High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequently limited in low- and middle-income countries (LMICs). In Mexico, variability in HD-MTX practices may compromise treatment safety and efficacy. This study aimed to characterize national practice patterns and identify context-specific adaptations in the delivery of HD-MTX in resource constrained settings. Methods: A nationwide, cross-sectional electronic survey was conducted between May and November 2023 among pediatric hematologists and oncologists treating patients younger than 18 years with ALL. The questionnaire assessed institutional guidelines, availability of pharmacokinetic monitoring, and supportive care practices, including hydration, urinary alkalinization, and folinic acid rescue. Data were analyzed descriptively. Results: A total of 111 specialists from 27 Mexican states participated. Only 56% reported having institutional HD-MTX guidelines. While 97% administered HD-MTX to high-risk ALL patients, only 61% used full protocol-recommended doses, and nearly one-third reported dose reductions. Methotrexate plasma level monitoring was only available in 56% of centers. Most centers (86%) administered HD-MTX exclusively in the inpatient setting. Supportive care practices varied substantially across institutions and risk groups. Reported barriers included limited laboratory capacity (61%), lack of standardized protocols (44%), and delays related to bed availability (39%). Conclusions: Optimizing HD-MTX delivery in Mexico requires integrating standardized clinical practices with targeted system-level interventions to ensure timely access to pharmacokinetic monitoring. The development and implementation of context-adapted national guidelines may improve safety, reduce variability in care, and mitigate outcome disparities in children with ALL.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500469
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL
PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (<21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT). RESULTS: Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures. CONCLUSION: Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (2) , e2500469
Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL
PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (<21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT). RESULTS: Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures. CONCLUSION: Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.
- 5 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32075
Clinical and Economic Impact of the Mexico in Alliance With St. Jude Golden Hour Collaborative in a Mexican Hospital
Background: In low‐ and middle‐income countries, infections remain the leading cause of treatment‐related mortality in pediatric patients with cancer. To address this, the Golden Hour Collaborative—developed in Mexico in alliance with St. Jude—was designed to promote timely antibiotic administration for febrile pediatric hemato‐oncology patients through a multidisciplinary approach, continuous caregiver and staff training, standardized protocols, and supply availability. This study evaluates the clinical and economic impact of implementing the MAS Collaborative at the ISSEMyM Maternal–Infant Hospital. Procedure: A prospective cohort study with historical controls was conducted. Outcomes were analyzed with nonparametric tests. Costs per febrile neutropenia (FN) episode were estimated using official state cost tables (adjusted to 2025 USD). Results: A total of 160 episodes were analyzed: 80 in the pre‐intervention period (2015–2018) and 80 in the post‐intervention period (2019–2022). After implementation, the proportion of patients receiving antibiotics within 60 min increased from 3.8% to 98% (median time‐to‐antibiotic (TTA) 198 vs. 42 min, p < 0.001). Outcomes improved with shorter hospital stays (9 vs. 8 days, p = 0.03), reduced pediatric intensive care unit (PICU) admissions (20% vs. 7.5%, OR 0.32, p = 0.02), decreased septic shock (25% vs. 8.7%), and no infection‐related deaths post‐intervention (vs. 7.5% pre‐intervention). Discharge without complications rose from 50% to 83%. Mean healthcare cost decreased from USD 8,580 to USD 2,835. Conclusion: In this resource‐limited setting, the MAS Collaborative shows that multidisciplinary, context‐adapted interventions can improve timeliness of care, reduce complications and mortality, and lower short‐term costs, highlighting their potential for scalability in LMICs.
- 5 October 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (12) , e32075
Clinical and Economic Impact of the Mexico in Alliance With St. Jude Golden Hour Collaborative in a Mexican Hospital
Background: In low‐ and middle‐income countries, infections remain the leading cause of treatment‐related mortality in pediatric patients with cancer. To address this, the Golden Hour Collaborative—developed in Mexico in alliance with St. Jude—was designed to promote timely antibiotic administration for febrile pediatric hemato‐oncology patients through a multidisciplinary approach, continuous caregiver and staff training, standardized protocols, and supply availability. This study evaluates the clinical and economic impact of implementing the MAS Collaborative at the ISSEMyM Maternal–Infant Hospital. Procedure: A prospective cohort study with historical controls was conducted. Outcomes were analyzed with nonparametric tests. Costs per febrile neutropenia (FN) episode were estimated using official state cost tables (adjusted to 2025 USD). Results: A total of 160 episodes were analyzed: 80 in the pre‐intervention period (2015–2018) and 80 in the post‐intervention period (2019–2022). After implementation, the proportion of patients receiving antibiotics within 60 min increased from 3.8% to 98% (median time‐to‐antibiotic (TTA) 198 vs. 42 min, p < 0.001). Outcomes improved with shorter hospital stays (9 vs. 8 days, p = 0.03), reduced pediatric intensive care unit (PICU) admissions (20% vs. 7.5%, OR 0.32, p = 0.02), decreased septic shock (25% vs. 8.7%), and no infection‐related deaths post‐intervention (vs. 7.5% pre‐intervention). Discharge without complications rose from 50% to 83%. Mean healthcare cost decreased from USD 8,580 to USD 2,835. Conclusion: In this resource‐limited setting, the MAS Collaborative shows that multidisciplinary, context‐adapted interventions can improve timeliness of care, reduce complications and mortality, and lower short‐term costs, highlighting their potential for scalability in LMICs.
- Open Access
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- 18 August 2024
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 6) , S193-S201
Open AccessOvercoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center
- Open Access
- 1 July 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (Suppl 2) , S25-S29
Real-world practice of acute leukemia intrathecal chemotherapy administration: A Mexican nationwide survey
- 1 July 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 45 (Suppl 2) , S25-S29
Open AccessReal-world practice of acute leukemia intrathecal chemotherapy administration: A Mexican nationwide survey
- 15 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30140
Escalated doses of methotrexate and L‐asparaginase in critically ill children with a concurrent diagnosis of acute lymphoblastic leukemia and appendicitis
- 15 December 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30140
Escalated doses of methotrexate and L‐asparaginase in critically ill children with a concurrent diagnosis of acute lymphoblastic leukemia and appendicitis
- Open Access
- 30 August 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 971-976
Diagnosis and treatment of acute lymphoblastic leukemia in Latin America
To discuss the status and challenges associated with the management of acute lymphoblastic leukemia (ALL) in Latin America.This review summarizes various insights gained from information regarding ...
- 30 August 2022
- Published by Taylor & Francis in Hematology
- Vol. 27 (1) , 971-976
Open AccessDiagnosis and treatment of acute lymphoblastic leukemia in Latin America
To discuss the status and challenges associated with the management of acute lymphoblastic leukemia (ALL) in Latin America.This review summarizes various insights gained from information regarding ...
- 26 April 2022
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 54 (2) , 360-366
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature
Immune thrombocytopenia (ITP) is an autoimmune disease that results from antibody-mediated platelet destruction and impaired platelet production. Novel therapies have emerged in the last decade, but 15–20% of patients will relapse or fail and require further therapy. We performed a prospective, single-arm intervention study on seven patients with chronic, persistent, or refractory ITP from the Hospital Universitario “Dr. José E González”, in Monterrey, Mexico between 2015 and 2019. Eligible patients received oral oseltamivir 75 mg twice daily for 5 days and were followed up for six months. Most patients received a median of three distinct therapies (range 2–6). Four patients (57.1%) received combined therapy. The median time for any response was 55.5 days (range = 14–150). All patients responded at some point in time (ORR = 100%, six had a proportion of loss of response [PR], and one achieved [CR]). Six months after oseltamivir administration, three patients (42.9%) maintained a response, and one patient had a CR (14.3%). Oseltamivir was well tolerated with a good overall response rate and was useful for treating chronic ITP. We observed an initial increase in the number of platelets; however, this response was not maintained.
- 26 April 2022
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 54 (2) , 360-366
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature
Immune thrombocytopenia (ITP) is an autoimmune disease that results from antibody-mediated platelet destruction and impaired platelet production. Novel therapies have emerged in the last decade, but 15–20% of patients will relapse or fail and require further therapy. We performed a prospective, single-arm intervention study on seven patients with chronic, persistent, or refractory ITP from the Hospital Universitario “Dr. José E González”, in Monterrey, Mexico between 2015 and 2019. Eligible patients received oral oseltamivir 75 mg twice daily for 5 days and were followed up for six months. Most patients received a median of three distinct therapies (range 2–6). Four patients (57.1%) received combined therapy. The median time for any response was 55.5 days (range = 14–150). All patients responded at some point in time (ORR = 100%, six had a proportion of loss of response [PR], and one achieved [CR]). Six months after oseltamivir administration, three patients (42.9%) maintained a response, and one patient had a CR (14.3%). Oseltamivir was well tolerated with a good overall response rate and was useful for treating chronic ITP. We observed an initial increase in the number of platelets; however, this response was not maintained.
- Open Access
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (7) , e29498
Cancer does not wait: Safeguarding care for pediatric acute lymphoblastic leukemia patients during the COVID‐19 pandemic in a Mexican hospital
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (7) , e29498
Open AccessCancer does not wait: Safeguarding care for pediatric acute lymphoblastic leukemia patients during the COVID‐19 pandemic in a Mexican hospital